Baird served as a co-manager on this offering
AboutMersana Therapeutics, Inc. (“Mersana” or the “Company”) (NASDAQ-GS:MRSN) recently completed an underwritten public offering of 9,200,000 shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional 1,200,000 shares of common stock, at a public offering price of $19.00 per share. The gross proceeds to Mersana from the offering are expected to be $174.8 million.
Mersana is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, XMT-1536, is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersana’s second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana’s customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company’s early stage programs include a B7-H4 targeting ADC, as well as a STING-agonist ADC developed using the Company’s Immunosynthen platform. In addition, multiple partners are using Mersana’s Dolaflexin platform to advance their ADC pipelines. Mersana Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
CONTACT US TO LEARN MORE
- June 2020
- Mersana Therapeutics, Inc.
- Target Location
- North America